Cancer Forums and News by PhD's

News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Cancer cells spread by releasing 'bubbles', according to an MUHC study
By Dross at 2008-04-22 08:38

Montreal, April 21, 2008 – A new fundamental mechanism of how tumour cells communicate has just been discovered by the team of Dr. Janusz Rak at the Research Institute of the McGill University Health Centre (MUHC) in collaboration with Dr Guha from the University of Toronto. The cancer cells are able to communicate with their more healthy counter-parts by releasing vesicles. These bubble-like structures contain cancer-causing (oncogenic) proteins that can trigger specific mechanisms when they merge into non or less-malignant cells. These findings could change our view on how cancerous tissues work and lead to major clinical innovations. They were published on April 20 in the on-line edition of Nature Cell Biology.

read more | 1 comment | 1103 reads

MIT IDs link between brain tumor proteins
By Dross at 2007-07-21 00:24

MIT researchers have identified a critical link between two proteins found in brain tumors, a discovery that could eventually help treat a form of brain cancer that kills 99 percent of patients.

Glioblastoma multiforme (GBM), the most aggressive brain tumor in adults, strikes about 15,000 people in the United States each year. GBM is currently treated with a combination of surgery, radiation and chemotherapyterm, but those treatments have proven ineffective. Most patients die within a year.

Now, MIT scientists have uncovered a connection between two proteins found in the tumor cells, and they have demonstrated that attacking both of those proteins kills tumor cells much more effectively than targeting either one alone.

read more | 1539 reads

Lung cancer-derived EGFR mutants exhibit intrinsic differences in inhibitor sensitivity
By Dross at 2007-03-13 22:20

A new study sheds light on how some small-molecule tyrosine kinase inhibitors, including two that are currently being used clinically to treat cancer, interact with wild-type and mutated forms of the epidermal growth factor receptor (EGFRtermtermterm). The research, published in the March issue of the journal Cancer Cell, published by Cell Press, may help to guide rational use of currently available EGFR inhibitors and provides new direction for the design and development of even more potent inhibitors that are tailored to specific EGFR mutants.

Many human malignancies exhibit mutated forms of the EGFR, a tyrosine kinase that plays a critical role in signaling pathways controlling cell proliferation and survival. Although the specific mechanisms are unclear, studies have shown that some EGFR mutations are associated with increased sensitivity to small-molecule tyrosine kinase inhibitors. To better understand how distinct mutant EGFRs interact with inhibitors on a structural level, Dr. Michael J. Eck from Harvard Medical School and the Dana-Farber Cancer Institute and colleagues studied the enzyme activity of two lung cancer-derived EGFR mutants and determined their crystal structures when bound to several different commonly used inhibitors.

read more | 2636 reads

Novel EGFR antibody outperforms cetuximab in mouse model of lung cancer
By Dross at 2007-01-27 00:28


Antibodies that selectively bind and destroy cancer cells represent some of the most promising cancer therapy approaches being developed today. Several of these antibodies have reached the market, including cetuximabtermterm (Erbituxterm, ImClone Systems), which targets the epidermal growth factor receptor (EGFRtermtermterm) protein. However, a study conducted at the Dana-Farber Cancer Institute and the Ludwig Center at Dana-Farber/Harvard Medical School now suggests that antibodies binding a particular protein conformation, caused by hyperactivation, might have distinct therapeutic advantages over antibodies, like cetuximab, that bind to wild-type (normal) target proteins.

read more | 2255 reads

Identification of Target Genes for Therapy in Laryngeal Squamous Cell Carcinoma
By HCat at 2007-01-23 10:37

    Researchers from Helsinki, Finland have conducted a gene copy number and RNA expression analysis of 20 laryngeal cancer cell lines and primary tumors. The common causes for head and neck squamous cell carcinomaterm (HNSCC) are tobacco and alcohol but clinical biomarkers for HNSCC management as well as molecular targets for therapy are lacking. This paper is rather technical but a vital step in elucidating the molecular mechanisms in HNSCC and providing new drug targets, since there has been no improvement in survival rates in the past 25 years for larynx cancer. This study focuses on squamous cell carcinoma, the most common type of malignant head and neck tumors. CCND1 and EGFRtermtermterm, as well as loss of tumor-suppressor genes are known to play an important role in the development of HNSCC. The HNSCC samples used show gene copy number changes either through deletions of DNA or duplications of DNA.

read more | 3502 reads

Antibody vs Antibody
By Dross at 2007-01-13 04:31

Panitumumabtermterm, otherwise known as Vectibixterm, is the first fully human monoclonal antibodyterm directed against the EGFRtermtermterm receptor which is expressed on the surface of 75% of colorectal cancers. It was also approved by the fda this month, so knowledge of its efficacy could help you in discussing options in the treatment of your cancer. Be sure to ask your doctor about this human antibody and be sure to use the name of the drug when discussing it rather than the term "antibody" as there are many antibodies currently being used or approved for the treatment of cancer. What is the difference between Erbituxterm and Vectibix? Vectibix, (the fully human derived antibody) showed a 3% lesser amount of rash type immunolgical reactions than Erbitux.

read more | 4675 reads

Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
By Dross at 2007-01-04 07:39

Research new Antibodies for your disease, and don't let you insurance company deny you if they say you are negative for EGFRtermtermterm Immunohistochemistry staining as the test has not been proven effective but the treatments are very expensive and pit the insurance company against you. One year of these types of treatments can cost up to $150,000.


[via Entrez PubMed]:

read more | 1217 reads

Her-1 EGFR mechanism of Tarceva video
By Dross at 2007-01-03 03:28

The Tarceva website has an interesting 3d video of the proposed mechanism of action of their drug. Interesting. Click here to watch


This was not a paid link.

2230 reads

FDA Approves a New Drug for Colorectal Cancer, Vectibix
By admin at 2006-11-22 10:47

The Food and Drug Administration (FDA) today approved Vectibixterm (panitumumabtermterm) for the treatment of patients with colorectal cancer that has metastasized (spread to other parts of the body) following standard chemotherapyterm. Vectibix, a monoclonal antibodyterm that binds to a protein called epidermal growth factor receptor or EGFRtermtermterm on some cancer cells, received an accelerated approval after showing effectiveness in slowing tumor growth and, in some cases, reducing the size of the tumor. In the United States, it is estimated that 150,000 new cases of colon cancer will be diagnosed and 55,000 deaths will occur from colon and rectal cancer in 2006. Approximately 70 percent of all colorectal carcinomas test positive for EGFR.

read more | 2229 reads

New Survival Study of Vandetanib (ZACTIMA(TM), ZD6474) in Patients With Advanced Lung Cancer
By admin at 2006-11-18 06:28
<p>Â*Â*Â*Â* <strong>First </strong>Patient Enrolled in Phase III International Randomised, Double-Blind, Placebo-Controlled Study of <strong>Vandetanib </strong>for Non-Small Cell Lung Cancer (NSCLC) </p><p>&nbsp;</p><p>After Failure of EGFR TKI Therapy AstraZeneca today announced the start of enrolment into a <strong>new </strong>Phase III study of the novel once-daily oral anti-cancer drug vandetanib (ZACTIMA(TM), ZD6474) as third/fourth line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following EGFR TKI therapy. </p><p>&nbsp;</p>
read more | 3053 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 12:00 AM.